Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Human Vaccines & Immunotherapeutics|December 15, 2016
Meningococcal serogroup B vaccines: Estimating breadth of coverageRobert G K Donald, Julio Cesar Hawkins, Li Hao, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
The Journal of Infectious Diseases|April 16, 2003
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremiaJoyce S Plested, Shannon L Harris, J Claire Wright, et al.
Vaccine|January 29, 2013
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|June 22, 2012
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trialHelen S Marshall, Peter C Richmond, Michael D Nissen, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus VaccineShelly Senders, Prakash Bhuyan, Qin Jiang, et al.
Vaccine|February 17, 2019
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescentsTimo Vesikari, Lars Østergaard, Johannes Beeslaar, et al.
Infectious Diseases and Therapy|July 24, 2020
MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 StudiesJohannes Beeslaar, Judith Absalon, Annaliesa S Anderson, et al.
Vaccine|July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsLars Østergaard, Timo Vesikari, Shelly D Senders, et al.
The Lancet. Infectious Diseases|October 18, 2016
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trialHelen S Marshall, Peter C Richmond, Johannes Beeslaar, et al.
Pageof 4